المؤلفون: Igle J. de Jong, Christian U. Blank, Thomas Powles, Roland Van Velthoven, Maureen J.B. Aarts, Michael A.S. Jewett, Sandrine Marreaud, Sandra Collette, Lori Wood, Sylvie Rottey, Harm H.E. van Melick, Peter F.A. Mulders, John B. A. G. Haanen, Axel Bex, Johannes V. Van Thienen, Jean Baptiste Lattouf, Bertrand Tombal, John Wagstaff, Laurence Collette, Roderick de Bruijn

المساهمون: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: European Urology, Vol. 76, no. 4, p. 437-440 (2019)
European Urology, 76, 437-440
European Urology, 76(4), 437-440. ELSEVIER SCIENCE BV
European Urology, 76(4), 437-440. Elsevier
European Urology, 76, 4, pp. 437-440

مصطلحات موضوعية: medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, PLANNED NEPHRECTOMY, urologic and male genital diseases, THERAPY, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, RENAL-CELL CARCINOMA, Renal cell carcinoma, law, Cytoreductive nephrectomy, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Medicine, Adverse effect, Surgical safety, business.industry, Sunitinib, Mortality rate, Retrospective cohort study, Common Terminology Criteria for Adverse Events, medicine.disease, EFFICACY, Nephrectomy, female genital diseases and pregnancy complications, Surgery, 030220 oncology & carcinogenesis, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0e7e8b92600ad6a6b0194b11b05123Test
https://doi.org/10.1016/j.eururo.2019.06.006Test

المؤلفون: Christian U. Blank, Tim O'Brien, Ekaterini Boleti, John B. A. G. Haanen, John Peters, Simon Horenblas, Naveed Sarwar, Jonathan Shamash, Luis Beltran, Paul Nathan, Anju Sahdev, Simon Chowdhury, Axel Bex, Daniel M. Berney, Thomas Powles

المصدر: European urology. 60(3)

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Indoles, Time Factors, Urology, medicine.medical_treatment, Antineoplastic Agents, Kaplan-Meier Estimate, Nephrectomy, Risk Assessment, Disease-Free Survival, Drug Administration Schedule, Clinical Trials, Phase II as Topic, Renal cell carcinoma, Risk Factors, Internal medicine, medicine, Carcinoma, Sunitinib, Humans, Pyrroles, Prospective Studies, Prospective cohort study, Survival rate, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Neoadjuvant therapy, Aged, Proportional Hazards Models, business.industry, Patient Selection, Middle Aged, medicine.disease, Kidney Neoplasms, Neoadjuvant Therapy, Survival Rate, Clear cell renal cell carcinoma, Treatment Outcome, Chemotherapy, Adjuvant, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2e9085f490f30d0fb7de98c3a9c9c6Test
https://pubmed.ncbi.nlm.nih.gov/21680083Test